<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276314</url>
  </required_header>
  <id_info>
    <org_study_id>97-1413A3</org_study_id>
    <nct_id>NCT01276314</nct_id>
  </id_info>
  <brief_title>Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions</brief_title>
  <official_title>Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions (SCAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe skin adverse drug reactions can result in death. Toxic epidermal necrolysis (TEN) has
      the highest mortality (30-35%); Stevens-Johnson syndrome and transitional forms correspond to
      the same syndrome, but with less extensive skin detachment and a lower mortality (5-15%).
      Hypersensitivity syndrome, sometimes called Drug Reaction with Eosinophilia and Systemic
      Symptoms (DRESS), has a mortality rate evaluated at about 10%. The aims of this project are
      (1) to compare the effect of treatment between systemic steroid and anti-TNF-α. Including
      skin healing time, beginning of re-epithelialization time, internal organ recovery time,
      mortality rate, adverse events and (2) to investigate the molecular mechanism of severe
      cutaneous adverse reaction after anti-TNF-α treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe cutaneous adverse drug reactions, including Toxic epidermal necrolysis (TEN),
      Stevens-Johnson syndrome(SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
      is a life threatening disease. There is no gold standard in the therapy of SCAR. Treatment
      with high dose systemic corticosteroids is controversial. Although there have been recent
      reports of success with various therapies such as plasmapheresis and high-dose intravenous
      immunoglobulins, their efficacy is not yet proven. Assessment of these therapies is difficult
      because of their non-specific immunosuppressant or immunomodulating modes of action. Recent
      studies have shown evidence of the pathogenetic importance of tumour necrosis factor (TNF)-a,
      suggesting a new therapeutic approach in selective blockade of TNF-a using specific
      antibodies. We report successful treatment TEN using monoclonal IgG anti-TNF-antibodies. The
      aims of this project are (1) to compare the effect of treatment between systemic steroid and
      anti-TNF-α. Including skin healing time, beginning of re-epithelialization time, internal
      organ recovery time, mortality rate, adverse events and (2) to investigate the molecular
      mechanism of severe cutaneous adverse reaction after anti-TNF-α treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin Healing Time</measure>
    <time_frame>One to two months for SJS/TEN cases, and one to six months for DRESS cases.</time_frame>
    <description>Healing was defined as complete re-epithelialization (i.e., the complete absence of erosions). We recorded the time taken by the skin to heal.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Drug Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>anti- TNF-a treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti- TNF-a</intervention_name>
    <description>25mg BIW, SC</description>
    <arm_group_label>anti- TNF-a treatment</arm_group_label>
    <other_name>Etanercept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>1-1.5 mg / kg / day</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>steroid therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient with clinical and pathological diagnoses of severe cutaneous
             adverse drug reactions such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis or
             Durg reaction with eosinophilia and systemic symptoms.

          2. Male or female patient aged more than 4 years.

          3. Inform consent obtained.

        Exclusion Criteria:

          1. Pregnant or breastfeeding female.

          2. Allergic to any anti-TNF-α biological product.

          3. Active or latent tuberculosis confirmed with Chest X-ray.

          4. Severe active infection and septicemia.

          5. Active Hepatitis B or C carrier.

          6. Suspected HIV carrier with CD4 count less than 200.

          7. Patient with poor compliance or with safety concerns judged by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Hung Chung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Dermatology, CGMH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Chang Gung Memorial hospital</name>
      <address>
        <city>Taipei</city>
        <zip>105</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Piérard GE. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol. 2000 Oct;22(5):413-7.</citation>
    <PMID>11048976</PMID>
  </reference>
  <results_reference>
    <citation>Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008 Jan;58(1):33-40. Epub 2007 Oct 4.</citation>
    <PMID>17919775</PMID>
  </results_reference>
  <results_reference>
    <citation>Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014 Aug;71(2):278-83. doi: 10.1016/j.jaad.2014.04.044. Epub 2014 Jun 11.</citation>
    <PMID>24928706</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <results_first_submitted>November 3, 2017</results_first_submitted>
  <results_first_submitted_qc>December 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 19, 2017</results_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCAR</keyword>
  <keyword>anti-TNF-a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
    <mesh_term>Drug Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>SCAR patients were enrolled in the clinical trial from 2009 to 2015 at Chang Gung Memorial Hospital in Taiwan.</recruitment_details>
      <pre_assignment_details>We totally recruited 140 participants, but only 135 SCAR participants (including 91 SJS/TEN patients and 44 DRESS patients) were enrolled to analyze. 5 participants in the control group were not included to analyze (3 cases failed a screening with CD4&lt;200 cells/mm3 and 2 cases as diagnosis change).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Anti- TNF-a Treatment (SJS/TEN)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
anti-TNF a: 25mg BIW, SC</description>
        </group>
        <group group_id="P2">
          <title>Control Group (SJS/TEN)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
        </group>
        <group group_id="P3">
          <title>Anti- TNF-a Treatment (DRESS)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
anti-TNF a: 25mg BIW, SC</description>
        </group>
        <group group_id="P4">
          <title>Control Group (DRESS)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 135 SCAR patients (including 91 SJS/TEN cases and 44 DRESS cases) were enrolled to analyze.</population>
      <group_list>
        <group group_id="B1">
          <title>Anti- TNF-a Treatment (SJS/TEN)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
anti-TNF a: 25mg BIW, SC</description>
        </group>
        <group group_id="B2">
          <title>Control Group (SJS/TEN)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
        </group>
        <group group_id="B3">
          <title>Anti- TNF-a Treatment (DRESS)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
anti-TNF a: 25mg BIW, SC</description>
        </group>
        <group group_id="B4">
          <title>Control Group (DRESS)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.73" spread="16.78"/>
                    <measurement group_id="B2" value="59.84" spread="24.20"/>
                    <measurement group_id="B3" value="53.95" spread="17.41"/>
                    <measurement group_id="B4" value="60.95" spread="20.39"/>
                    <measurement group_id="B5" value="56.53" spread="20.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Skin Healing Time</title>
        <description>Healing was defined as complete re-epithelialization (i.e., the complete absence of erosions). We recorded the time taken by the skin to heal.</description>
        <time_frame>One to two months for SJS/TEN cases, and one to six months for DRESS cases.</time_frame>
        <population>We determined if the enrolled participants had SJS/TEN and DRESS using the criteria and histopathological examinations.</population>
        <group_list>
          <group group_id="O1">
            <title>Anti- TNF-a Treatment (SJS/TEN)</title>
            <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
anti-TNF a: 25mg BIW, SC</description>
          </group>
          <group group_id="O2">
            <title>Control Group (SJS/TEN)</title>
            <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
          </group>
          <group group_id="O3">
            <title>Anti- TNF-a Treatment (DRESS)</title>
            <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
anti-TNF a: 25mg BIW, SC</description>
          </group>
          <group group_id="O4">
            <title>Control Group (DRESS)</title>
            <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Healing Time</title>
          <description>Healing was defined as complete re-epithelialization (i.e., the complete absence of erosions). We recorded the time taken by the skin to heal.</description>
          <population>We determined if the enrolled participants had SJS/TEN and DRESS using the criteria and histopathological examinations.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.75" lower_limit="4" upper_limit="41"/>
                    <measurement group_id="O2" value="19" lower_limit="7" upper_limit="42"/>
                    <measurement group_id="O3" value="40.5" lower_limit="18" upper_limit="117"/>
                    <measurement group_id="O4" value="34" lower_limit="9" upper_limit="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For evaluating the time taken to heal skin erosion, the Kaplan-Meier product-limit estimates method was performed. Differences were considered statistically significant at P values of less than 0.05.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>The p-value was analyzed for SJS/TEN participants with &gt;10% body surface area detachment.</p_value_desc>
            <method>Kaplan-Meier analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For evaluating the time taken to heal skin erosion, the Kaplan-Meier product-limit estimates method was performed. Differences were considered statistically significant at P values of less than 0.05.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>This p-value was analyzed for DRESS participants.</p_value_desc>
            <method>Kaplan-Meier analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>one to two months</time_frame>
      <desc>The endpoints of serious adverse event and adverse event were assessed for three weeks after discharge.</desc>
      <group_list>
        <group group_id="E1">
          <title>Anti- TNF-a Treatment (SJS/TEN)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
anti-TNF a: 25mg BIW, SC</description>
        </group>
        <group group_id="E2">
          <title>Control Group (SJS/TEN)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
        </group>
        <group group_id="E3">
          <title>Anti- TNF-a Treatment (DRESS)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Etanercept administration:
The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks
anti-TNF a: 25mg BIW, SC</description>
        </group>
        <group group_id="E4">
          <title>Control Group (DRESS)</title>
          <description>Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
Fill out the case report form
Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
Drug administration:
The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper GI hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Stridor, vocal cord palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI hemorrhage (grade 2)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="48"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Drug Hypersensitivity Clinical and Research Center, Laboratory of Dr. Wen-Hung Chung,</name_or_title>
      <organization>Chang Gung Memorial Hospital, Linko</organization>
      <phone>886-3-328-1200 ext 8494</phone>
      <email>kiruamairo@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

